News | Clinical Decision Support | July 10, 2018

Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging

Agreement aims to develop and market software solutions to aid physicians' in their treatment recommendations and follow-up care for liver cancer

Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging

July 10, 2018 — Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an artificial intelligence (AI) software solution to support liver cancer diagnostics. The AI software will focus on utilizing computed tomography (CT) and magnetic resonance imaging (MRI), and care.

Through this collaboration, Guerbet and IBM Watson Health plan to co-develop clinical decision support solutions. The first, called Watson Imaging Care Advisor for Liver [1], is planned to be a diagnostic support tool that will use AI to automate the detection, staging, tracking, monitoring, and therapy prediction and response of primary and secondary liver cancer for clinicians. The IBM Research team will also work on development of the solutions leveraging prior research innovations.

Liver cancer is the second leading cause of cancer death worldwide,[2] and the fastest growing cause of cancer deaths in the United States.[3] About 83 percent of primary liver cancer cases occur in developing countries.[4] The liver is also a common site for metastases, particularly in the case of digestive cancers, in which nearly 50 percent of patients develop metastases.[5] The hope is that better characterization and earlier identification of these metastases may lead to an improvement in the chances of recovery.

Care Advisor for Liver will be designed to be compatible with the most common picture archiving and communication systems (PACS), making it easy to be integrated directly into the workflows of healthcare professionals.

Watson Imaging Care Advisor for Liver will be a part of a family of decision support tools powered by IBM Watson image analytics designed to inform radiologists' diagnostic decisions for their patients. These offerings are being developed with a shared objective to create insights derived from IBM Watson image analytics to help inform clinical decisions.

For more information: www.guerbet.com, www.ibm.com/watson/health

References

[1] Care Advisor is not yet a formally approved product name.

[2] http://www.who.int/news-room/fact-sheets/detail/cancer

[3] http://pressroom.cancer.org/LiverCancer2017

[4] https://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/liver-cancer-statistics

[5] https://www.sciencedirect.com/science/article/pii/S2211568414000941

Related Content

Keeping the health and safety of of the HIMSS audience in mind, the conference moves to August 9-13 in Las Vegas
News | HIMSS | August 03, 2020
August 3, 2020 —  The Healthcare Informatio...
Candelis, Inc., a leading provider of innovative and cost-effective enterprise healthcare solutions, and VasoTechnololgy, a subsidiary of the Vaso Corporation, announced an agreement to distribute Candelis' suite of image management PACS solutions and cloud services, including ImageGrid, ImageGrid Mini PACS and ASTRA Cloud.
News | Enterprise Imaging | July 29, 2020
July 29, 2020 — Candelis, Inc., a leading provider of innovative and cost-effective enterprise healthcare solutions,
Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

News | Prostate Cancer | July 28, 2020
July 28, 2020 — A study published in 
Zebra Medical Vision announced its sixth FDA 510(k) clearance for its mammography solution, HealthMammo, which has already received a CE mark. Zebra Medical’s algorithm empowers breast radiologists by prioritizing and identifying suspicious mammograms, providing a safety net for radiologists. The suspicious mammograms are identified faster and read earlier than the current “first-in first-out” standard of care. 
News | Breast Imaging | July 27, 2020
July 26, 2020 —  Zebra Medical Vision announced its sixth FDA 510
Clearing medical device cybersecurity requirements from DoD delivers even more safety assurance for customers
News | Cybersecurity | July 23, 2020
July 23, 2020 — Carestream Health’s ImageView software has received the Risk Management Framework Authority to Operat